Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 2/7/17 → 2/7/20 |
Funding
- PPD Investigator Services, LLC (Prot #GSK 201585 // Prot #GSK 201585)
- GlaxoSmithKline LLC (Prot #GSK 201585 // Prot #GSK 201585)
Prot #GSK 201585: A Phase III, randomized, multicenter, parallel-group, noninferiority, open-label study evaluating the efficacy, safety, and tolerability of switching to long-acting cabotegravir plus longacting rilpivirine from current INI- NNRTI-, or PI
- Taiwo, Babafemi O (PD/PI)
Project: Research project